Speaker
Description
In the last few years there has been an expanding concern about osteoporosis due to its constantly growing prevalence and its enormous socio-economic impact.1 As an alternative to conventional treatments, combination therapies, including gene therapy, have emerged with promising results. However, the transport and delivery of those molecules still remains a challenge.2
In this work, we propose a new system based on mesoporous silica nanoparticles (MSNs) able to co-deliver nucleic acids and osteogenic peptides through systemic injection to bone tissue. The nanoparticle administration produced an increased expression of certain osteogenic related genes, improving the bone microarchitecture and achieving osteoporosis remission. In particular, the importance of this work relies on the achievement of delivering both molecules with remarkable results. The treated osteoporotic mice recovered values of healthy animals. The osteoporosis remission in these animals was achieved by using a MSNs-based system designed for co-delivering small interfering RNAs and an osteogenic peptide such as osteostatin.3 The designed system was able to protect and deliver both biomolecules to the target tissue by systemic administration modifying gene expression and improving bone microarchitecture. To the best of our knowledge, this is the first time that MSNs have been employed in a combination therapy for the treatment of osteoporosis, which has leaded to promising results of bone recovery in osteoporotic animals.
References
1. J.E. Compston, M.R. McClung, W.D. Leslie. LANCET, 2019, 393, 364.
2. M. Manzano, M. Vallet-Regí. Adv. Funct. Mater., 2020, 30, 1902634
3. P. Mora-Raimundo, D. Lozano, M. Manzano, M. Vallet-Regí. ACS Nano, 2019, 13, 5451
| Speaker Country | Spain |
|---|